Patents Assigned to The Secretary of the Department of Health and Human Services,
-
Patent number: 11897845Abstract: Provided is a compound of formula (I) in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.Type: GrantFiled: January 10, 2022Date of Patent: February 13, 2024Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, VANDERBILT UNIVERSITY, THE UAB RESEARCH FOUNDATION, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: David J. Maloney, Alex Gregory Waterson, Ganesh Rai Bantukallu, Kyle Ryan Brimacombe, Plamen Christov, Chi V. Dang, Victor Darley-Usmar, Xin Hu, Ajit Jadhav, Somnath Jana, Kwangho Kim, Jennifer L. Kouznetsova, William J. Moore, Bryan T. Mott, Leonard M. Neckers, Anton Simeonov, Gary Allen Sulikowski, Daniel Jason Urban, Shyh Ming Yang
-
Patent number: 11897933Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: GrantFiled: June 11, 2021Date of Patent: February 13, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng
-
Patent number: 11898166Abstract: Disclosed are methods of preparing thymic organoids according to embodiments of the invention. Also disclosed are methods of preparing thymic emigrant cells in vitro, according to embodiments of the invention. Also disclosed are methods of treating or preventing a condition in a mammal, e g., cancer.Type: GrantFiled: September 19, 2018Date of Patent: February 13, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Raul E. Vizcardo, Nicholas P. Restifo
-
Patent number: 11898207Abstract: Disclosed are methods of isolating paired T cell receptor (TCR) alpha and beta chain sequences, or an antigen-binding portion thereof. Also disclosed are methods of automatically identifying the TCR alpha and beta chain V segment sequences and CDR3 sequences of a TCR having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Methods of preparing a population of cells that express paired TCR alpha and beta chain sequences, or an antigen-binding portion thereof, are also disclosed. Isolated pairs of TCR alpha and beta chain sequences and isolated populations of cells prepared by the methods are also disclosed.Type: GrantFiled: March 28, 2018Date of Patent: February 13, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Yong-Chen Lu, Peter Fitzgerald, Zhili Zheng, Steven A. Rosenberg
-
Patent number: 11897875Abstract: The present invention relates to novel alpha5 subunit-selective negative allosteric modulators of GABAA receptors that have been deuterated to improve their medicinal properties by prolonging their half-lives, rendering them useful as fast-acting pharmaceutical treatments for depression related disorders.Type: GrantFiled: August 9, 2022Date of Patent: February 13, 2024Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Scott Thompson, Adam Van Dyke, Craig Thomas, Patrick Morris
-
Publication number: 20240041978Abstract: Methods are disclosed herein for modulating osteoclast fusion. In some embodiments, these methods include administering an effective amount of a Lupus autoantigen (La) protein, or an agent that modulates La protein expression or activity, to a subject in need thereof, thereby modulating osteoclast fusion in the subject. In some embodiments, the method increases osteoclast fusion and bone resorption. In other embodiments, the method decreases osteoclast fusion and bone resorption.Type: ApplicationFiled: March 3, 2022Publication date: February 8, 2024Applicant: The U.S.A., as Represented by the Secretary, Department of Health and Human ServicesInventors: Leonid V. Chernomordik, Evgenia Leikina, Jarred M. Whitlock
-
Publication number: 20240041650Abstract: Disclosed are devices and methods for delivering a sheet of tissue into the eye in such a way that damage to the tissue is minimized, damage to the eye during insertion and manipulation of the tissue is minimized, and the tissue is released and delivered in a precise and controlled fashion.Type: ApplicationFiled: August 14, 2023Publication date: February 8, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventor: Arvydas Maminishkis
-
Publication number: 20240041906Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.Type: ApplicationFiled: August 17, 2023Publication date: February 8, 2024Applicant: The U.S.A., as Represented by the Secretary, Department of Health and Human ServicesInventors: Walid Heneine, Thomas M. Folks, Robert Janssen, Ronald A. Otten, Jose Gerardo Garcia Lerma
-
Patent number: 11890339Abstract: Embodiments of immunogens comprising a recombinant Nipah virus (NiV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also provided are embodiments of immunogens comprising chimeric proteins comprising the recombinant NiV F ectodomain trimer and one or more G ectodomains, a multimer of NiV G ectodomains, and protein nanoparticles comprising the recombinant NiV F ectodomain trimer or an NiV G ectodomain. Also disclosed are nucleic acids encoding the immunogens and methods of their production. Methods for inducing an immune response in a subject by administering a disclosed immunogen to the subject are also provided. In some embodiments, the immune response treats or inhibits NiV infection in a subject.Type: GrantFiled: August 5, 2019Date of Patent: February 6, 2024Assignees: The United States of Americam as represented by the Secretary, Department of Health and Human Services, Trustees of Dartmouth CollegeInventors: Barney Graham, Rebecca Loomis, Guillaume Stewart-Jones, John Mascola, Jason McLellan
-
Patent number: 11890340Abstract: Disclosed herein are methods of treating or preventing a lung disorder comprising administering to a subject a composition comprising an agent that modulates activity and/or expression of Epithelial Membrane Protein 2 (EMP2) in an amount effective to treat or prevent the lung disorder and compositions useful in such for methods.Type: GrantFiled: April 30, 2019Date of Patent: February 6, 2024Assignee: The United States of America as Represented By The Secretary of the Department of Health and Human ServicesInventors: Michael Brian Fessler, Carmen J. Williams, Wan-Chi Lin
-
Patent number: 11883431Abstract: Provided is a mammalian T cell modified to express the Phf19 at a level that is higher than the level of Phf19 expressed by a T cell that has not been modified to express Phf19. Provided is a genetically-modified mammalian T cell comprising a genetic expression vector comprising (a) virally-, bacterially-, or both virally- and bacterially-derived genetic sequences and (b) a genetic sequence encoding Phf19, whereby the genetic sequence encoding Phf19 within the vector is expressed within the T cell. Pharmaceutical compositions, methods of treating a disease, and methods of inhibiting the differentiation of T cells by epigenetic reprogramming are also provided.Type: GrantFiled: June 5, 2018Date of Patent: January 30, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Yun Ji, Luca Gattinoni
-
Publication number: 20240027470Abstract: Biomarkers tests which can be used to predict a positive or negative risk of preeclampsia are described. More specifically, a panel of biomarkers including MMP-7 and gpIIbIIIa, described. The test is useful to predict preeclampsia when a biological sample is obtained between the 16th and 22nd week of pregnancy. Prediction later in pregnancy can be achieved by a combination of Siglec-6, Activin A, ALCAM, and/or FCN2.Type: ApplicationFiled: October 6, 2023Publication date: January 25, 2024Applicants: Wayne State University, The United States of America, as Represented by the Secretary, Department of Health & Human ServicesInventors: Adi L. Tarca, Piya Chaemsaithong, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
-
Patent number: 11878998Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.Type: GrantFiled: November 11, 2021Date of Patent: January 23, 2024Assignee: The United States of America, as represented by the Secretary Department of Health and Human ServicesInventors: Peter Kwong, Barney Graham, John Mascola, Li Ou, Aliaksandr Druz, Man Chen, Wing-Pui Kong, Ivelin Stefanov Georgiev, Emily Rundlet, Michael Gordon Joyce, Yaroslav Tsybovsky, Paul Thomas, Marie Pancera, Mallika Sastry, Cinque Soto, Joseph Van Galen, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Ulrich Baxa
-
Patent number: 11878052Abstract: Chimeric antigen receptors (CARs) containing CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making CAR T cells are also disclosed.Type: GrantFiled: January 27, 2020Date of Patent: January 23, 2024Assignees: Lentigen Technology, Inc., The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
-
Patent number: 11879017Abstract: The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.Type: GrantFiled: August 24, 2021Date of Patent: January 23, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Richard A Morgan, Steven A. Rosenberg
-
Patent number: 11872261Abstract: Described herein is the design and construction of a class of lipoprotein targeting protease inhibitors. Small peptides with protease inhibitor activity are conjugated to hydrophobic, lipoprotein targeting molecules using, for instance, amine reactive chemistry. Methods of use of the resultant lipoprotein targeting protease inhibitor (antiprotease) molecules are also described. Also described is the production and use of protease inhibitor enriched HDL particles, as well as A1AT-peptide-enriched HDL particles, and their use in various therapeutic contexts.Type: GrantFiled: February 16, 2022Date of Patent: January 16, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Alan T. Remaley, Scott M. Gordon
-
Publication number: 20240009290Abstract: The disclosure provides immunogen polypeptides comprising fragments of VAR2CSA protein expressed by P. falciparum. Aspects of the disclosed immunogen polypeptides comprise all or portions of the CSA binding regions of VAR2CSA as identified by a structural study of VAR2CSA conducted by the inventors. Also provided are compositions comprising such immunogen polypeptides, and methods of using the immunogen polypeptides for vaccination and treatment of disease.Type: ApplicationFiled: November 18, 2021Publication date: January 11, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Niraj H. Tolia, Rui Ma, Patrick E. Duffy, Jonathan P. Renn
-
Patent number: 11865172Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.Type: GrantFiled: September 10, 2021Date of Patent: January 9, 2024Assignees: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., CORNELL RESEARCH FOUNDATION, INC., THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTIONInventors: Patti Cynthia Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, Nancy J. Cox, William L. Castleman
-
Patent number: 11865168Abstract: Provided herein are compositions and methods for therapeutic and/or prophylactic treatment of an intracellular bacterial infection in a subject in need thereof, comprising one or more modulating agents, wherein the one or more modulating agents increase expression of IFN?, IL-2, TNF, and/or IL-17 in systemic and/or lung T cells. In some embodiments, the increase of expression of IFN?, IL-2, TNF, and/or IL-17 occurs in lung T cells. The lung T cells can be lung resident T cells or systemic T cells that are recruited to the lung. In some embodiments, the T cells are CD4+ and/or CD8+ T cells. In some embodiments, the intracellular bacterial infection is a Mycobacterium tuberculosis (MTB) infection.Type: GrantFiled: December 30, 2020Date of Patent: January 9, 2024Assignees: Massachusetts Institute of Technology, The United States of America, as represented by The Secretary, Department of Health & Human Services, University of Pittsburgh—Of The Commonwealth System of Higher EducationInventors: Alexander K. Shalek, Travis Hughes, Marc H. Wadsworth, Robert Seder, Mario Roederer, Joanne L. Flynn, Patricia Darrah
-
Publication number: 20240002445Abstract: Disclosed is a class of knotted cyclic peptides. Related pharmaceutical compositions and methods of using the peptides and methods of synthesizing the peptides are also disclosed.Type: ApplicationFiled: November 17, 2021Publication date: January 4, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Barry R. O'Keefe, Lauren R. Haugh Krumpe, Yves Pommier, Christophe R. Marchand, Ingrid C. Schroeder, K. Johan Rosengren, Brice A.P. Wilson